Cyclooxygenase-2 in Barrett's esophagus, Barrett's adenocarcinomas, and esophageal SCC: ready for clinical trials

Am J Gastroenterol. 1999 Aug;94(8):2313-5. doi: 10.1111/j.1572-0241.1999.02313.x.

Authors

R V Lord¹, K D Danenberg, P V Danenberg

Affiliation

¹ Department of Surgery, University of Southern California, Los Angeles, USA.

PMID: 10445576
DOI: 10.1111/j.1572-0241.1999.02313.x

No abstract available

MeSH terms

Adenocarcinoma / drug therapy
Adenocarcinoma / genetics*
Adenocarcinoma / pathology
Barrett Esophagus / drug therapy
Barrett Esophagus / genetics*
Barrett Esophagus / pathology
Carcinoma, Squamous Cell / drug therapy
Carcinoma, Squamous Cell / genetics*
Carcinoma, Squamous Cell / pathology
Clinical Trials as Topic
Cyclooxygenase 2
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors / therapeutic use*
Gene Expression Regulation, Neoplastic / drug effects
Humans
Isoenzymes / genetics*
Membrane Proteins
Neoplasm Staging
Nitric Oxide Synthase / genetics
Precancerous Conditions / drug therapy
Precancerous Conditions / genetics*
Precancerous Conditions / pathology
Prognosis
Prostaglandin-Endoperoxide Synthases / genetics*
Tumor Cells, Cultured

Substances

Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Isoenzymes
Membrane Proteins
Nitric Oxide Synthase
Cyclooxygenase 2
PTGS2 protein, human
Prostaglandin-Endoperoxide Synthases